 |
|
|
| |
EDP-514, A NOVEL PANGENOTYPIC CLASS II HEPATITIS B
VIRUS CORE INHIBITOR: PRELIMINARY RESULTS OF A 28-DAY
PHASE 1b STUDY IN NUC-SUPPRESSED CHB PATIENTS
|
| |
| |
AASLD 2021 Nov 12-15
Jordan J. Feld1, Eric Lawitz2, Tuan Nguyen3, Jacob Lalezari4, Tarek Hassanein5, Paul Martin6, Steven-Huy Han7, Douglas Dieterich8, Jeanne-Marie Giard9, Guy De La Rosa10, Alaa Ahmad10, Ed Luo10, Annie L. Conery10, Nathalie Adda10
1Toronto Centre for Liver Disease, University Health Network, Toronto, Canada, 2Texas Liver Institute, San Antonio, Texas, USA, 3Tuan Nguyen MD Gastroenterology and Hepatology, San Diego, California, USA, 4Quest Clinical Research, San Francisco, California, USA, 5Southern California Research Center, Coronado, California, USA, 6Gastroenterology, University of Miami, Florida, USA, 7University of California, Los Angeles, Los Angeles, California, USA, 8Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA, 9Centre Hospitalier Universitaire de Montréal, Montréal, Québec, Canada, 10Enanta Pharmaceuticals, Inc., Watertown, Massachusetts, USA
|
| |
|
|
|
|
|
